Harald Rinde, MD, MBA – Principal

Dr. Rinde has over 20 years experience in the Pharmaceutical and Biotechnology industries in senior management positions developing and commercializing a broad range of products, including Novartis’ $5 billion Diovan (for treatment of hypertension) and $1 billion Femara (for treatment of breast cancer). His area of expertise also includes health-economics with a specialization in pharmaceutical and diagnostic product health economic modeling, healthcare structure and practices in developing and developed countries and quantification of product and service opportunities in the healthcare market. Dr. Rinde is a Principal at BioBridge Strategies, a global consulting firm that identifies how pharmaceutical, biotech and diagnostic companies can optimally develop and position their unique technologies or products for maximum clinical and economic impact in the healthcare marketplace. BioBridge Strategies develops strategic and operational solutions for young and mature companies focusing on the “new biology”. Dr. Rinde has practiced as a General Practitioner in Norway and worked in General and Plastic Surgery in Norway and the United States. He received his MD degree from the Royal College of Surgeons in Dublin, Ireland and his MBA from the Kellogg School of Management, Northwestern University in Evanston, Illinois. Dr. Rinde is fluent in Norwegian and conversational in Swedish, Danish and German.

< Back to Team